bicalutamide has been researched along with Androgen-Independent Prostatic Cancer in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 45 (68.18) | 24.3611 |
| 2020's | 21 (31.82) | 2.80 |
| Authors | Studies |
|---|---|
| Ban, F; Cavga, AD; Chang, MEK; Chen, G; Cherkasov, A; Flory, MR; Ghaidi, F; Gleave, ME; Huang, CF; Lack, NA; Lallous, N; Lawn, S; Leblanc, E; Lingadahalli, S; Mohammed, H; Mohan, S; Morin, H; Rennie, PS; Young, RN; Yu, IPL | 1 |
| Wang, S; Xiang, W | 1 |
| Carpenter, V; Faber, AC; Gewirtz, DA; Harada, H; Min Lee, S; Murray, G; Reed, J; Saleh, T; Souers, A | 1 |
| Egawa, S; Enei, Y; Fukuokaya, W; Hata, K; Iwamoto, Y; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Obayashi, K; Onuma, H; Otsuka, T; Sakanaka, K; Sano, T; Shimomura, T; Suzuki, H; Tsuzuki, S; Yanagisawa, T | 1 |
| Agarwal, N; Armstrong, AJ; Concepcion, RS; Duggan, W; Dunshee, CJ; Haas, GP; Higano, CS; Karsh, LI; Olsson, CA; Penson, DF; Shen, Q; Sugg, J | 1 |
| Gu, S; Li, S; Liu, J; Sun, F; Wang, G; Wei, D; Yang, T; Zhang, Y | 1 |
| Ito, T; Koie, T; Miyake, H; Naiki, T; Nakane, K; Shiroki, R; Sugiyama, Y; Takahara, K; Yasui, T | 1 |
| Cao, J; Du, X; Liang, Z; Peng, Y; Shi, J; Tian, L; Yang, K; Zhang, J | 1 |
| Cardoso, AM; Maia, CJ; Nascimento, D; Passarinha, L; Rocha, SM; Socorro, S | 1 |
| Bi, J; Wang, J; Zhang, G; Zhang, X | 1 |
| Abe, H; Amiya, Y; Hayashi, S; Kaneko, Y; Kimura, N; Nakatsu, H; Shima, T; Suzuki, N; Takei, A; Tetsuka, T; Uchida, T | 1 |
| Cao, J; Du, X; Liang, Z; Lin, Q; Liu, H; Shen, Y; Shi, J; Tian, L; Yang, X; Zhang, J; Zhang, R | 1 |
| Fukuoka, K; Hayashi, T; Inoue, S; Kadonishi, Y; Kajiwara, M; Kobayashi, K; Matsubara, A; Mita, K; Nagamatsu, H; Shigeta, M; Tacho, T; Teishima, J | 1 |
| Adachi, T; Deguchi, T; Harimoto, K; Hase, T; Iguchi, T; Ishii, K; Iwamoto, K; Iwata, H; Kanamaru, T; Kato, M; Machida, Y; Morimoto, K; Nakatani, T; Ohmachi, T; Takegaki, Y; Tamada, S; Tashiro, K; Yamamoto, S; Yasuda, S | 1 |
| Akamatsu, S; Fujimoto, Y; Inoue, T; Kimura, T; Kobayashi, T; Matsubara, N; Mori, K; Murakami, K; Ogawa, O; Terada, N | 1 |
| Funahashi, Y; Gotoh, M; Matsukawa, Y; Muramatsu, T; Sassa, N; Yamamoto, A | 1 |
| Gu, Y; He, M; Peng, Y; Qu, F; Sun, J; Wang, G; Wang, Q; Zhou, F | 1 |
| Bouamar, H; Gu, X; Houghton, PJ; Qin, T; Sun, LZ; Wang, B; Wang, Y; Xia, L; Yang, J; Zeballos, C; Zhang, W; Zhou, Y; Zhu, H | 1 |
| Fujita, K; Imamura, R; Kawashima, A; Kiuchi, H; Koh, Y; Miyagawa, Y; Nagahara, A; Nonomura, N; Uemura, M; Ujike, T | 1 |
| Brás, LA; Cardoso, HJ; Carvalho, TMA; Figueira, MI; Madureira, PA; Oliveira, PJ; Sardão, VA; Socorro, S; Vaz, CV | 1 |
| Deng, G; Fang, Q; Huang, S; Ji, H; Jia, M; Li, W; Liao, Q; Meng, M | 1 |
| Pienta, KJ; Reyes, DK | 1 |
| Chow, K; Clarke, D; Cmero, M; Corcoran, NM; Costello, AJ; Dundee, P; Grima, C; Grummet, J; Hovens, CM; Howard, N; Kerger, M; Kurganovs, NJ; Macintyre, G; Mangiola, S; McCoy, P; Ngyuen, A; Norden, S; Parente, P; Peters, JS; Ruljancich, P; Ryan, A; Stuchbery, R | 1 |
| Beggs, RE; Bose, S; Crapuchettes, ME; D'Abronzo, LS; deVere White, RW; Durbin-Johnson, BP; Ghosh, PM; Melgoza, FU; Mudryj, M; Siddiqui, S; Tepper, CG; Vinall, RL | 1 |
| Baron, B; Chowdhury, S; Hasabou, N; Heidenreich, A; Klotz, L; Lin, P; Shore, ND; Siemens, DR; van Os, S; Villers, A; Wang, F | 1 |
| Haffner, MC; Höti, N; Hu, Y; Shah, P; Yang, S; Zhang, H | 1 |
| Lei, BH; Lu, ZJ; Wang, Y; Zhang, Y; Zhu, QY; Zou, Q | 1 |
| Anai, S; Fujimoto, K; Inoue, T; Miyake, M; Nakai, Y; Tanaka, N | 1 |
| Barlev, A; Brown, BA; Chowdhury, S; Concepcion, RS; Flanders, SC; Karsh, LI; Klotz, LH; Penson, DF; Schultz, NM; Shore, ND; Yang, H | 1 |
| Alumkal, JJ; Babb, J; Barnett, ES; Beer, TM; DiPaola, R; Ferrari, AC; Gomez-Pinillos, A; Liu, X; Moore, D; Stein, MN; Taplin, ME | 1 |
| Egawa, S; Furusato, B; Honda, M; Kamata, Y; Kimura, S; Kimura, T; Kiyota, H; Koike, Y; Sato, S; Takahashi, H; Tashiro, K; Yorozu, T | 1 |
| Barbosa, FG; Buchpiguel, CA; Costa, LB; Dzik, C; Marin, JFG; Nunes, RF; Queiroz, MA | 1 |
| Di Cesare, E; Festuccia, C; Gravina, GL; Jannini, EA; Lenzi, A; Mancini, A; Marampon, F; Motta, M; Muzi, P; Negri-Cesi, P; Piccolella, M; Tombolini, V | 1 |
| Ha, YS; Jung, YS; Kim, IY; Kim, JH; Kim, WJ; Lee, GT | 1 |
| Beraldi, E; Crafter, C; Davies, BR; Fazli, L; Gleave, ME; Kim, S; Lamoureux, F; Thaper, D; Thomas, C; Zoubeidi, A | 1 |
| Chung, J; Chung, JM; Ha, YS; Jung, YS; Kang, DI; Kim, IY; Kim, TH; Kim, WJ; Lee, DH; Lee, GT; Min, K; Moon, KH | 1 |
| Azad, AA; Beardsley, EK; Chi, KN; Chin, J; Ellard, SL; Hotte, SJ; Klotz, L; Kollmannsberger, C; Mukherjee, SD | 1 |
| Bai, X; Danielpour, D; Montano, MM; Song, K; Wittmann, BM; Yeh, IJ | 1 |
| Hagiwara, M; Hayakawa, N; Ito, Y; Maeda, T; Matsumoto, K; Nagata, H; Nakamura, S; Ninomiya, A; Tanaka, N | 1 |
| Goodman, MM; Kawai, K; Kobayashi, M; Nakanishi, T; Oka, S; Okudaira, H; Ono, M; Schuster, DM; Shirakami, Y; Tamai, I | 1 |
| Booth, CM; Chi, KN; Golubovic, J; Gregg, R; Harris, P; Joshua, AM; Murray, N; Sridhar, SS; Wang, L | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Franco, OE; Hayward, SW; Jin, R; Matusik, RJ; Wang, J; Wang, Y; Yamashita, H; Yu, X | 1 |
| Dagvadorj, A; Ellsworth, E; Gu, L; Gupta, S; Hoang, DT; Koptyra, M; Leiby, B; Liao, Z; Merry, DE; Mirtti, T; Montie, H; Nevalainen, MT; Savolainen, S; Shen, F; Talati, PG; Tan, SH | 1 |
| Aoki, Y; Corey, E; Emura, T; Honma, A; Houjo, T; Ishikura, N; Kawata, H; Nakagawa, T; Nakamura, R; Nishimoto, A; Ohta, M; Sato, H; Shiraishi, T; Tachibana, K; Tsunenari, T; Vessella, RL; Watanabe, M; Yoshino, H | 1 |
| Cao, QF; Chen, YF; Qi, J; Qian, SB; Shen, HB; Zhang, L | 1 |
| Chang, C; Dang, Q; He, D; Li, L; Liang, L; Song, W; Xie, H; Yang, Z; Yeh, S | 1 |
| Armstrong, C; Gao, AC; Liu, C; Lou, W; Sandher, A; Zhu, Y | 1 |
| Chu, FM; Gomella, L; Hereghty, B; Manyak, MJ; Rudo, T; Sartor, O; Somerville, MC | 1 |
| Butler, LM; Carter, SL; Centenera, MM; Gillis, JL; Grose, RH; Marrocco-Tallarigo, DL; Tilley, WD | 1 |
| Cork, D; Davies, BR; Gaughan, L; Grey, J; Guo, W; Jones, D; Nakjang, S; O'Neill, D; Robson, CN; Wade, M; Wedge, SR | 1 |
| Chaytor, L; Gaughan, L; Grey, J; Jones, D; Nakjang, S; Robson, CN; Wade, M | 1 |
| Abd Elmageed, ZY; Abdel-Mageed, AB; Ambs, S; Crawford, BE; Datta, A; Davis, R; Hudson, RS; Jia, D; Kim, H; Moparty, K; Moroz, K; Srivastav, S; Thomas, R; Yang, Y | 1 |
| Daniels, G; Deng, F; Du, X; Lee, P; Li, Y; Melamed, J; Monaco, ME; Ren, Q; Wang, J; Wang, LH; Wu, X; Yang, Y; Ye, F; Zhang, D; Zhang, V | 1 |
| Bhattacharya, S; Chowdhury, S; Hasabou, N; Heidenreich, A; Klotz, L; Shore, ND; Siemens, DR; van Os, S; Villers, A; Wang, F | 1 |
| Agarwal, N; Armstrong, AJ; Concepcion, R; Dunshee, C; Higano, CS; Karsh, L; Krivoshik, A; Olsson, C; Penson, DF; Phung, D; Wang, F; Wu, K | 1 |
| Awrey, S; Azad, AA; Cherkasov, A; Chi, KN; Collins, CC; Gleave, ME; Lallous, N; LeBihan, S; Leblanc, E; Murillo, J; Rennie, PS; Singh, K; Tse, R; Volik, SV; Wyatt, AW | 1 |
| Beckett, LA; Chow, H; Dall'Era, MA; deVere White, R; Evans, CP; Ghosh, PM; Lara, PN; Li, Y; Pan, CX; Yap, SA | 1 |
| Choi, H; Kim, EJ; Lee, SH; Um, SJ | 1 |
| Baron, B; Chowdhury, S; Heidenreich, A; Holmstrom, S; Ivanescu, C; Klotz, L; Lin, P; Shore, ND; Siemens, DR; Villers, A; Wang, F | 1 |
| Bryce, AH; Castle, EP; Dueck, AC; Ho, TH; Hou, YX; Joseph, RW; Northfelt, DW; Nunez-Nateras, R; Stanton, ML; Wong, B | 1 |
| Chen, Y; He, D; Li, L; Lv, W; Pei, X; Shang, H; Wang, X; Xie, H | 1 |
| Daizumoto, K; Dondoo, TO; Fukawa, T; Fukumori, T; Kanayama, HO; Kohzuki, M; Kowada, M; Kusuhara, Y; Mori, H; Nakatsuji, H; Takahashi, M | 1 |
| Chen, J; Deng, C; Guo, S; Han, H; Li, Z; Wang, Y; Yang, X; Yao, K; Yu, X; Zhang, Z; Zhou, F; Zhou, Q | 1 |
| Appleman, L; Beumer, JH; Holleran, JL; Kim, KP; Lewis, LD; Morris, MJ; Parise, RA; van Erp, N | 1 |
| Biordi, L; Festuccia, C; Ficorella, C; Gravina, GL; Jannini, EA; Marampon, F; Motta, M; Piccolella, M; Tombolini, V | 1 |
3 review(s) available for bicalutamide and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Therapeutic Strategies to Target the Androgen Receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Topics: Androgen Receptor Antagonists; Humans; Male; Network Meta-Analysis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome | 2023 |
Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chlormadinone Acetate; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Humans; Kallikreins; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2014 |
14 trial(s) available for bicalutamide and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
Topics: Androgen Antagonists; Anilides; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Treatment Outcome | 2022 |
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Treatment Outcome | 2020 |
Loss of
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligopeptides; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Snail Family Transcription Factors; Tosyl Compounds | 2021 |
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
Topics: Age Factors; Aged; Anilides; Antineoplastic Agents; Benzamides; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Treatment Outcome | 2018 |
[Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer].
Topics: Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Goserelin; Humans; Male; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tosyl Compounds; Treatment Outcome | 2017 |
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
Topics: Aged; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Male; Mice; Middle Aged; Nitriles; Panobinostat; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds; Xenograft Model Antitumor Assays | 2019 |
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Indazoles; Kallikreins; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sulfonamides; Tosyl Compounds; Treatment Outcome | 2015 |
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; Double-Blind Method; Dutasteride; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Multivariate Analysis; Nitriles; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds | 2015 |
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Topics: Aged; Aged, 80 and over; Anemia; Anilides; Arthralgia; Back Pain; Benzamides; Constipation; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyspnea; Fatigue; Fractures, Spontaneous; Heart Failure; Hot Flashes; Humans; Hydronephrosis; Hypertension; Male; Middle Aged; Myocardial Infarction; Nausea; Nitriles; Patient Dropouts; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds | 2016 |
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Benzamides; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds | 2016 |
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; TOR Serine-Threonine Kinases; Tosyl Compounds | 2016 |
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
Topics: Anilides; Antineoplastic Agents; Benzamides; Cancer Pain; Carcinoma; Double-Blind Method; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Tosyl Compounds; Treatment Outcome | 2017 |
A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Anilides; Drug Combinations; Estrogen Antagonists; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Raloxifene Hydrochloride; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2017 |
49 other study(ies) available for bicalutamide and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Development of 2-(5,6,7-Trifluoro-1
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Development; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms, Castration-Resistant; Quinolines; Receptors, Androgen; Structure-Activity Relationship | 2021 |
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Cellular Senescence; Docetaxel; Humans; Male; Mice; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sulfonamides; Tosyl Compounds; Xenograft Model Antitumor Assays | 2021 |
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Humans; Japan; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Nonsteroidal Anti-Androgens; Prednisolone; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Tosyl Compounds | 2022 |
Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cytoskeletal Proteins; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Male; Mice; Nitriles; Nuclear Proteins; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2022 |
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Androstenes; Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2022 |
The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer.
Topics: Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Male; NF-E2-Related Factor 2; Prostatic Neoplasms, Castration-Resistant; Tamoxifen | 2022 |
STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.
Topics: Androgen Antagonists; Antigens, Neoplasm; Humans; Male; Nitriles; Oxidoreductases; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Upfront Androgen Receptor-Axis-Targeted Therapies in Men with De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies | 2023 |
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-α/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
Topics: Aged; Anilides; Animals; Aromatase; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Estrogen Receptor alpha; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Letrozole; Male; Matrix Metalloproteinase 12; Mice; Middle Aged; Neoplasm Metastasis; Nitriles; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Up-Regulation | 2019 |
Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Chlormadinone Acetate; Flutamide; Humans; Male; Middle Aged; Nitriles; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Tosyl Compounds | 2020 |
Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Follow-Up Studies; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2020 |
A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Topics: Aged; Anilides; Disease Progression; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Temperature; Tosyl Compounds | 2019 |
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells.
Topics: Amino Acids; Androgen Receptor Antagonists; Anilides; Benzamides; Cell Line, Tumor; Cell Survival; Glutathione; Humans; Male; Metabolome; Metabolomics; Nitriles; Nucleosides; Oxazoles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins; Tosyl Compounds | 2020 |
Gli2 mediates the development of castration‑resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Progression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Mice; Nitriles; Nuclear Proteins; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Tosyl Compounds; Xenograft Model Antitumor Assays; Zinc Finger Protein Gli2 | 2020 |
Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kallikreins; Leuprolide; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Testosterone; Tosyl Compounds | 2020 |
Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
Topics: Amino Acid Transport System ASC; Androgens; Anilides; Animals; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Glucose; Glutaminase; Glutamine; Glycolysis; Humans; Lactic Acid; Lipid Metabolism; Male; Minor Histocompatibility Antigens; Models, Biological; Neoplasm Proteins; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rats; Sulfides; Thiadiazoles; Tosyl Compounds | 2021 |
The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Binding, Competitive; Cell Line, Tumor; Drug Resistance, Neoplasm; Heterografts; Humans; Male; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Nitriles; Prostatic Neoplasms, Castration-Resistant; Pseudogenes; RNA, Long Noncoding; RNA, Messenger; RNA, Neoplasm; Securin; Tosyl Compounds; Tumor Stem Cell Assay; Up-Regulation | 2021 |
Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds | 2021 |
The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Everolimus; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice, Nude; Nitriles; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Protein Serine-Threonine Kinases; Purines; Receptors, Androgen; Serine; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays | 2017 |
Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.
Topics: Androgens; Anilides; Animals; Cell Line, Tumor; Cell Movement; Fucose; Fucosyltransferases; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Xenograft Model Antitumor Assays | 2018 |
Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.
Topics: Aged; Aged, 80 and over; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Disease-Free Survival; Flutamide; Humans; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2018 |
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Humans; Male; Middle Aged; Nitriles; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Research Design; Tosyl Compounds | 2018 |
Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Female; Gene Expression Profiling; Heterografts; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger; Testosterone; Tosyl Compounds | 2019 |
Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment.
Topics: Aged, 80 and over; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antigens, Surface; Brachytherapy; Disease Progression; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Goserelin; Humans; Ligands; Male; Nitriles; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Tosyl Compounds | 2019 |
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Castration; Cell Line, Tumor; ErbB Receptors; Exportin 1 Protein; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Karyopherins; Male; Mice; Mice, Nude; Nitriles; Phenotype; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Androgen; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Tosyl Compounds | 2013 |
Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Benzamides; Benzofurans; Bone Morphogenetic Protein 6; Cell Line, Tumor; Dihydrotestosterone; Humans; Interleukin-6; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Mice; Nitriles; Phenylthiohydantoin; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Quinolines; Receptors, Androgen; Tosyl Compounds; Up-Regulation | 2013 |
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Topics: Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays | 2013 |
Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.
Topics: Adult; Androgen Antagonists; Anilides; Bone Morphogenetic Protein 6; Bone Neoplasms; Cell Communication; Cell Growth Processes; Cell Line, Tumor; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins; Receptors, Androgen; Retrospective Studies; Stromal Cells; Tosyl Compounds; Wnt Proteins; Wnt-5a Protein | 2014 |
HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Enhancer Elements, Genetic; Epithelial Cells; Gene Expression; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Male; Metribolone; Nitriles; Nuclear Proteins; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Transport; Receptors, Androgen; Repressor Proteins; RNA-Binding Proteins; Tosyl Compounds; Transcription Factors; Transcriptional Elongation Factors | 2014 |
Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.
Topics: Amino Acid Transport Systems; Androgens; Anilides; Carboxylic Acids; Cell Line, Tumor; Cyclobutanes; Dihydrotestosterone; Fluorine Radioisotopes; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Radioactive Tracers; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Androgen; Tosyl Compounds | 2014 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Male; NF-kappa B; Nitriles; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Benzamides; Cell Line, Tumor; Cell Survival; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Nitriles; Phenylthiohydantoin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Receptors, Androgen; Signal Transduction; STAT5 Transcription Factor; Tosyl Compounds; Tumor Suppressor Proteins | 2015 |
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Humans; Male; Mice; Molecular Docking Simulation; Mutation; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Transport; Receptors, Androgen; Sulfonamides; Thiohydantoins; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Follow-Up Studies; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Tosyl Compounds | 2015 |
Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Topics: Anilides; Animals; Benzamides; Cell Line, Tumor; Heterografts; Humans; Male; MAP Kinase Signaling System; Mast Cells; Matrix Metalloproteinase 9; Mice; Neoplasm Invasiveness; Neoplastic Stem Cells; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Long Noncoding; Tosyl Compounds | 2015 |
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Rhodamines; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Topics: Androgen Receptor Antagonists; Anilides; Apoptosis; Benzoquinones; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatin Immunoprecipitation; Gene Expression Profiling; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Lactams, Macrocyclic; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 2015 |
Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.
Topics: Androgen Antagonists; Anilides; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Immediate-Early Proteins; Male; Molecular Targeted Therapy; Mutation; Nitriles; Oligonucleotide Array Sequence Analysis; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Serine-Threonine Kinases; Receptors, Androgen; RNA Interference; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; Kallikreins; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tosyl Compounds | 2015 |
Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.
Topics: Alternative Splicing; Androgens; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Heterogeneous-Nuclear Ribonucleoprotein Group F-H; Humans; Male; MicroRNAs; Middle Aged; Nitriles; Nuclear Receptor Coactivator 3; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Receptors, Androgen; Response Elements; RNA Interference; Tosyl Compounds | 2016 |
ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
Topics: Anilides; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coenzyme A Ligases; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Nude; Neoplasm Invasiveness; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA Interference; Signal Transduction; Time Factors; Tosyl Compounds; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Topics: Androgen Receptor Antagonists; Anilides; Benzamides; DNA; Drug Resistance, Neoplasm; Flutamide; High-Throughput Nucleotide Sequencing; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2016 |
CACUL1 functions as a negative regulator of androgen receptor in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cullin Proteins; Gene Expression Regulation, Neoplastic; Histone Demethylases; Histones; Humans; Male; Methylation; Nitriles; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Receptors, Androgen; RNA Interference; Signal Transduction; Tosyl Compounds; Transcription, Genetic; Transfection | 2016 |
A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Orchiectomy; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Serum Albumin; Time Factors; Tosyl Compounds | 2017 |
Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Blood Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Galectin 3; Galectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Nitriles; Oligonucleotide Array Sequence Analysis; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transcription, Genetic; Xenograft Model Antitumor Assays | 2017 |
CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Casein Kinase II; Cell Line, Tumor; Drug Resistance, Neoplasm; Genetic Variation; Humans; Male; Naphthyridines; NF-kappa B; NF-kappa B p50 Subunit; Nitriles; Phenazines; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger; Signal Transduction; Tosyl Compounds; Transcription Factor RelA; Tumor Stem Cell Assay | 2017 |
Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.
Topics: Androstenes; Anilides; Benzamides; Chromatography, Liquid; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spectrometry, Mass, Electrospray Ionization; Tosyl Compounds | 2017 |
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Male; Mice, Nude; Morpholines; Nitriles; Orchiectomy; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Xenograft Model Antitumor Assays | 2011 |